Source: Virtual Congress 2020 – Translational therapeutic advances
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Joannes (Rennes, France), C. Morzadec (Rennes, France), F. Llamas Gutierrez (Rennes, France), D. Chiforeanu (Rennes, France), B. Richard De Latour (Rennes, France), L. Wollin (Biberach an der Riss, Germany), S. Jouneau (Rennes, France), L. Vernhet (Rennes, France). Antifibrotics effects of nintedanib on lung fibroblasts derived from patients with progressive fibrosing intertitial lung diseases. 3355

Member's Comments

No comment yet.

Related content which might interest you: Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019 Year: 2019 Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019 Clubbing in patients with fibrotic interstitial lung diseases Source: International Congress 2017 – ILDs: clinical problems Year: 2017 Experience with antifibrotics treatment in progressive interstitial lung diseases non-IPF Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases Year: 2021 Interstitial lung diseases and systemic disorders with lung involvement Source: ERS Skills Course 2017 - Summer school of paediatric respiratory medicine Year: 2017 Interstitial lung diseases and systemic disorders with lung involvement Source: ERS Skills Course 2016 Year: 2016 Genetic susceptibilty and manifestation of progressive fibrosing interstitial lung diseases. Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis Year: 2020 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Prevalence of progressive fibrosing interstitial lung disease Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 The natural history of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 55 (6) 2000085; 10.1183/13993003.00085-2020 Year: 2020 Comparison of clinical features between patients of lung cancer with combined pulmonary fibrosis and emphysema syndrome and those with interstitial pneumonia Source: Annual Congress 2012 - Diffuse parenchymal lung disease II Year: 2012 Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019 Year: 2019 Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2008; 32: 170-174 Year: 2008 Yoga in patients with fibrosing interstitial lung diseases – a feasibility trial Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 The efficacy of pirfenidone in scleroderma related interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Nitrofurantoin-induced interstitial lung disease Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012 Interstitial lung diseases in infants and children Source: Eur Respir J 2008; 31: 658-666 Year: 2008 The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype Source: Eur Respir Rev, 27 (150) 180077; 10.1183/16000617.0077-2018 Year: 2018